The treatment of hepatic encephalopathy

详细信息    查看全文

• 作者：Marsha Y. Morgan ; A. Blei ; K. Grüngreiff ; R. Jalan ; G. Kircheis ; G. Marchesini ; O. Riggio and Karin Weissenborn
• 关键词：Branched ; chain amino acids ; Bromocriptine ; Hepatic cirrhosis ; Hepatic encephalopathy ; Non ; absorbable antibiotics ; Non ; absorbable disaccharides ; Ornithine aspartate ; Sodium benzoate ; Treatment ; Zinc
• 刊名：Metabolic Brain Disease
• 出版年：2007
• 出版时间：December, 2007
• 年：2007
• 卷：22
• 期：3-4
• 页码：389-405
• 全文大小：645 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Neurosciences
  Neurology
  Biochemistry
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7365

文摘

Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.